Business Context and Reporting Period
This Form 8-K Current Report was filed by Dermata Therapeutics, Inc. on December 15, 2022. The Company is an emerging growth company incorporated in Delaware with its principal executive offices in San Diego, California. Its Common Stock (DRMA) and Warrants (DRMAW) are listed on The Nasdaq Capital Market.
Key Financial Metrics
This filing is a current report regarding listing status and risk factors. It does not provide specific financial data such as revenue, profit, cash flow, margins, debt, or liquidity metrics for the reporting period or any prior period.
Material Changes
The primary material event reported is the extension of a compliance period regarding Nasdaq listing requirements:
- Initial Notice: On June 17, 2022, Nasdaq notified the Company of non-compliance with the Minimum Bid Price Requirement (Rule 5550(a)(2)) due to the Common Stock closing below $1.00 per share for 30 consecutive business days.
- Initial Grace Period: The Company was granted 180 days to regain compliance, expiring December 14, 2022.
- Extension Granted: On December 15, 2022, Nasdaq granted an additional 180-day extension, setting a new compliance deadline of June 12, 2023.
Outlook, Risks, and Management Commentary
Management indicated it will continue to monitor the closing bid price and may consider available options to regain compliance, including a reverse stock split. The filing highlights significant risks associated with potential delisting:
- Delisting Consequences: Failure to regain compliance by June 12, 2023, could result in the delisting of Common Stock and Warrants.
- Market Impact: Delisting could substantially decrease trading volume, adversely affect market liquidity, and reduce market efficiencies.
- Financing and Confidence: The Company may face difficulties obtaining financing on acceptable terms, and delisting could lead to a loss of confidence among investors, suppliers, and employees.
- Stock Price Volatility: The announcement or implementation of a reverse stock split could negatively affect the stock price, and stockholders may lose some or all of their investment.
Investor Verification Checklist
- Verify the current closing bid price of DRMA to assess proximity to the $1.00 threshold.
- Monitor for any future announcements regarding the implementation of a reverse stock split.
- Review the Company's cash position in recent 10-Q or 10-K filings to evaluate its ability to fund operations if financing becomes difficult due to listing status.
- Check for any subsequent 8-K filings indicating a change in the compliance deadline or a formal delisting notice.